
Gastric Ulcers - Pipeline Insight, 2024
Description
Gastric Ulcers - Pipeline Insight, 2024
DelveInsight’s, Gastric Ulcers - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gastric Ulcers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gastric Ulcers: Overview
Gastric ulcers are a break in the mucosa of the stomach lining that penetrates through the muscularis mucosa and extends more than 5 mm in diameter. When alterations occur to the defense mechanisms of the stomach, it can cause changes in the gastric mucosa which will eventually result in erosion and then ulceration. This activity reviews the evaluation and management of gastric ulcers and explains the role of the interprofessional team in improving care for patients with this condition.
The most common etiologies of gastric ulcers include a bacterial infection with Helicobacter pylori and gastric prostaglandin loss associated with non-steroidal anti-inflammatory medications. Less common etiologies include hypergastrinemia (Zollinger-Ellison syndrome), viral infections such as CMV, chemotherapy and radiation, gastric outlet obstruction, gastric infiltrative disorders such as malignancy, cigarette smoking, and Crohn disease. The common factor in all of these etiologies is that they promote a breakdown in the mucosal barrier and expose the gastric mucosa to the damaging effects of acid.
The pathophysiology of gastric ulcer development depends on the insult. Since about 80 to 90% of gastric ulcers result from either Helicobacter pylori and/or NSAID use.
""Gastric Ulcers - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Ulcers pipeline landscape is provided which includes the disease overview and Gastric Ulcers treatment guidelines. The assessment part of the report embraces, in depth Gastric Ulcers commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Ulcers collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Gastric Ulcers. The therapies under development are focused on novel approaches to treat/improve Gastric Ulcers.
Gastric Ulcers Emerging Drugs
- Tegoprazan: RaQualia Pharma
Further product details are provided in the report……..
Gastric Ulcers: Therapeutic Assessment
This segment of the report provides insights about the Gastric Ulcers drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gastric Ulcers
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Gastric Ulcers: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Ulcers therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Ulcers drugs.
Gastric Ulcers Report Insights
- Gastric Ulcers Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gastric Ulcers drugs?
- How many Gastric Ulcers drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Ulcers?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastric Ulcers therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastric Ulcers and their status?
- What are the key designations that have been granted to the emerging drugs?
- RaQualia Pharma
- KindredBio
- Daewoong Pharmaceutical Co
- Pharmaking Ltd.
- Sam-A Pharm Co. Ltd.
- Xuanzhu Pharma Co
- Tegoprazan
- KIND-014
- Lansoprazole
- PMK S005
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Gastric Ulcers: Overview
- What is Gastric Ulcers?
- Types of Gastric Ulcers
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Gastric Ulcers– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Tegoprazan: RaQualia Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- PMK S005: PharmaKing
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Gastric Ulcers Key Companies
- Gastric Ulcers Key Products
- Gastric Ulcers- Unmet Needs
- Gastric Ulcers- Market Drivers and Barriers
- Gastric Ulcers- Future Perspectives and Conclusion
- Gastric Ulcers Analyst Views
- Gastric Ulcers Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.